Future research exploring the combination EGFR-TKIs plus anti-angiogenic agents and EGFR-TKIs alone should carefully document more accurate smoking status among enrolled patients to improve the reliability of results which could improve the clinical application of these therapies in patients with EGFR-mutated NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.